Celiac Panel Medication-Driven Changes: What Alters Your Results and How to Interpret Them

What the Celiac Panel Actually Measures

The standard celiac panel tests four analytes, each with a distinct biological target and a different sensitivity to external interference. Knowing which marker does what helps clinicians spot when a medication or diet is distorting the picture rather than reflecting true disease activity.

The Four Core Markers

Tissue transglutaminase IgA (tTG-IgA) is the first-line screening antibody. Sensitivity for untreated celiac disease is 90 to 95% and specificity is 95 to 97% in patients with normal total IgA [1]. It falls faster than any other marker after gluten removal.

Endomysial antibody IgA (EMA-IgA) uses indirect immunofluorescence. Specificity approaches 99%, but it is operator-dependent and costs more per test. EMA-IgA is used to confirm equivocal tTG-IgA results rather than as a standalone screen [2].

Deamidated gliadin peptide IgG (DGP-IgG) is the marker of choice when total IgA is low. It adds value in IgA-deficient patients and in young children under two, whose tTG-IgA responses may not yet be mature [3].

Total IgA is an internal control. If total IgA is <7 mg/dL (selective IgA deficiency), all IgA-based markers become unreliable and DGP-IgG or tTG-IgG must substitute.

Normal Ranges and Optimal Targets

Normal reference ranges differ by laboratory platform. As a general framework used across most U.S. Clinical labs:

| Marker | Negative (normal) | Equivocal | Positive | |---|---|---|---| | tTG-IgA | <4 U/mL | 4 to 10 U/mL | >10 U/mL | | EMA-IgA | Negative (titer) | 1:5 | >1:5 | | DGP-IgG | <20 U/mL | 20 to 30 U/mL | >30 U/mL | | Total IgA | 70 to 400 mg/dL | 7 to 70 mg/dL | <7 mg/dL (deficient) |

The ACG 2023 Clinical Guideline states: "We recommend tTG-IgA as the initial serological test for CD in patients over 2 years of age with adequate total IgA levels" [4]. For monitoring treated disease, an optimal target is a tTG-IgA that is not only below the assay's negative cutoff but showing a downward trend over consecutive draws.

How a Gluten-Free Diet Changes Every Marker

A gluten-free diet (GFD) is the most potent single intervention known to reduce celiac antibody titers. Starting a GFD before diagnostic testing is the most common source of false-negative serology in clinical practice [5].

Kinetics of Antibody Decline

TTG-IgA drops fastest. A prospective study following 683 newly diagnosed celiac patients found that median tTG-IgA normalized within 12 months of strict GFD adherence in adults, and within 6 months in children [6]. EMA-IgA lags behind. In the same cohort, 30% of adults still had detectable EMA-IgA at 24 months despite confirmed GFD adherence on repeat biopsy.

DGP-IgG behaves differently. It may fall within 3 to 6 months but can also rebound with even minor gluten exposures, making it a useful real-time dietary compliance marker [3].

Why Starting GFD Before Testing Is a Problem

Even two weeks of gluten restriction can drop tTG-IgA by 20 to 40% from peak, enough to shift a result from strongly positive to equivocal. The ACG guideline notes: "Patients should be on a gluten-containing diet prior to serologic testing; those already on a gluten-free diet require a formal gluten challenge or proceed directly to biopsy with HLA-DQ2/DQ8 genotyping" [4].

The Gluten Challenge Protocol

If a patient has already started a GFD before referral, the recommended reintroduction dose is at least 3 grams of gluten per day (roughly two slices of wheat bread) for a minimum of two weeks before repeat serology, and ideally six weeks before biopsy [7]. Shorter challenges produce unreliable titers. Patients should be counseled that symptoms may return and that this is expected and temporary.

Immunosuppressants and Biologic Agents

Immunosuppressive medications suppress antibody production globally, not just celiac-specific antibodies. This is a particularly important consideration in patients who have overlapping autoimmune conditions, a scenario that is not uncommon given that celiac disease co-occurs with autoimmune thyroid disease in roughly 5 to 10% of cases [8].

Corticosteroids

Systemic corticosteroids (prednisone, dexamethasone, methylprednisolone) reduce IgA secretion by downregulating B-cell activation and plasma cell differentiation. A patient on 20 mg/day of prednisone for an unrelated inflammatory condition may show tTG-IgA and EMA-IgA values in the negative range despite active villous atrophy. DGP-IgG is similarly suppressed, so no single IgA or IgG marker is reliable under high-dose steroid therapy. HLA-DQ2/DQ8 genotyping, which is unaffected by any medication, becomes the most useful adjunctive test in this scenario [4].

Methotrexate, Azathioprine, and Mycophenolate

These disease-modifying agents impair lymphocyte proliferation. Patients with rheumatoid arthritis or inflammatory bowel disease who are on azathioprine or methotrexate may have 40 to 60% lower antibody titers than an untreated patient with comparable mucosal damage [9]. Clinicians should note the immunosuppressant in the lab order and interpret serology with the understanding that titers underestimate disease activity.

Biologics Targeting TNF-alpha or IL Pathways

TNF-alpha inhibitors (adalimumab, infliximab) have a complex relationship with celiac serology. They do not directly suppress IgA synthesis but may reduce intestinal inflammation enough to lower tTG-IgA even in patients still consuming gluten. This mechanism is separate from a true GFD response and should not be mistaken for dietary compliance or resolution of celiac disease [10].

Proton-Pump Inhibitors and Acid Suppression

Proton-pump inhibitors (PPIs) such as omeprazole, pantoprazole, and esomeprazole do not directly suppress immunoglobulin synthesis. Their effect on celiac serology is indirect but clinically relevant.

The Microbiome and Barrier Hypothesis

Chronic PPI use alters the small intestinal microbiome, increases intestinal permeability, and raises the pH of the proximal gut. Higher luminal pH may change gluten peptide processing by intestinal proteases, potentially reducing the generation of the deamidated peptides that drive DGP-IgG production [11]. This effect is modest and does not reliably suppress tTG-IgA into the negative range on its own, but it may shift a borderline result toward equivocal.

Clinical Relevance

PPIs are highly prevalent in the celiac diagnostic workup population because dyspepsia and reflux are common presenting symptoms of untreated celiac disease. A patient on chronic omeprazole with a tTG-IgA of 6 U/mL (equivocal on a 0 to 10 scale) might reflect either early celiac disease muted by PPI or non-celiac gluten sensitivity with incidental PPI use. Duodenal biopsy and HLA typing remain the decision tools here, not repeat serology alone [4].

Iron, B12, and Folate Supplementation

Celiac disease is a leading cause of iron-deficiency anemia and vitamin B12 deficiency due to proximal small bowel malabsorption. These deficiencies are often the presenting finding before a celiac diagnosis is established. Understanding how supplementation affects the panel prevents a circular diagnostic error.

Iron Supplementation

Oral iron does not alter antibody titers directly. However, patients started on iron therapy for unexplained anemia sometimes improve their hemoglobin enough that clinicians attribute the anemia to iron deficiency alone and defer further workup. This delays celiac testing. The Endocrine Society and the ACG both recommend screening for celiac disease with a full panel in any patient with iron-deficiency anemia that lacks a clear gastrointestinal blood-loss source [4][12].

B12 and Folate

Neither cyanocobalamin nor methylcobalamin supplementation alters celiac antibody titers. Folate supplementation similarly has no direct effect on tTG-IgA, EMA-IgA, or DGP-IgG levels. The relevance here is interpretive: a patient whose B12 or folate normalizes on oral supplementation may appear to have resolved their malabsorption, masking ongoing villous atrophy. Serial celiac serology should continue even when micronutrient levels normalize.

Thyroid Medications and the Celiac-Thyroid Overlap

Autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease) co-occurs with celiac disease at a rate approximately 5-fold higher than expected by chance [8]. Patients on levothyroxine or methimazole are routinely screened for celiac disease in functional and integrative medicine settings, and this creates specific interpretation questions.

Levothyroxine Absorption and tTG-IgA

Untreated celiac disease impairs levothyroxine absorption by damaging the jejunum where T4 is primarily absorbed. A patient who requires persistently high levothyroxine doses (above 1.8 mcg/kg/day) to maintain a euthyroid TSH may warrant celiac screening regardless of GI symptoms [13]. Starting a GFD in this population often reduces the required levothyroxine dose by 15 to 30% within 6 months as mucosal healing occurs.

Levothyroxine itself does not alter celiac antibody titers. Methimazole, used in hyperthyroidism, has mild immunomodulatory properties but no documented effect on tTG-IgA or DGP-IgG in published literature.

Selenium

Selenium supplementation (200 mcg/day of selenomethionine) is sometimes used adjunctively in Hashimoto thyroiditis. A 2003 randomized controlled trial (N=70) found that selenium reduced thyroid peroxidase antibody titers by 36% vs. Baseline [14]. Selenium has no known direct effect on celiac antibody titers, but its immunomodulatory effects theoretically could influence the shared autoimmune milieu. No randomized data currently support or refute this for celiac serology specifically.

Dapsone, Hydroxychloroquine, and Dermatitis Herpetiformis

Dermatitis herpetiformis (DH) is the cutaneous manifestation of celiac disease. It is treated with dapsone and a strict GFD. Hydroxychloroquine is sometimes used off-label for autoimmune overlap conditions in the same patients.

Dapsone

Dapsone controls DH skin lesions within weeks but does not treat the underlying intestinal inflammation or normalize celiac serology. A patient on dapsone will still show elevated tTG-IgA if consuming gluten. After starting a GFD, tTG-IgA falls on a similar timeline as in intestinal celiac disease. Dapsone can then typically be tapered over 1 to 2 years as mucosal healing proceeds [15].

Hydroxychloroquine

Hydroxychloroquine inhibits toll-like receptor signaling and reduces autoantibody production broadly. It is used in lupus and rheumatoid arthritis and occasionally in undifferentiated connective tissue disease. Patients on hydroxychloroquine may show modestly lower tTG-IgA titers independent of dietary gluten intake, though this effect has not been studied in a dedicated celiac cohort. Clinicians should flag hydroxychloroquine use when interpreting borderline-positive celiac serology [9].

Monitoring the Panel Over Time: A Practical Framework

Serial celiac serology is the standard of care for monitoring GFD adherence and mucosal healing. The ACG recommends retesting tTG-IgA at 6 and 12 months after starting a GFD, then annually if stable [4].

Interpreting Persistent Elevation

If tTG-IgA remains above the negative cutoff at 12 months on a self-reported GFD, the differential includes:

1. Inadvertent gluten exposure (the most common cause)
2. Refractory celiac disease type I or II (rare, prevalence <1 to 2% of all celiac diagnoses)
3. Immunosuppressant use masking a more dramatic fall that would otherwise be expected
4. An intercurrent non-celiac autoimmune condition raising tTG-IgA independently (e.g., type 1 diabetes, autoimmune hepatitis) [16]

When to Rebiopsy

The 2023 ACG guideline does not recommend routine repeat biopsy in adults with normalized serology and resolution of symptoms. Repeat duodenal biopsy is indicated when tTG-IgA remains elevated after 12 to 24 months of strict GFD, when symptoms persist or worsen, or when refractory celiac disease is suspected [4].

The Role of HLA-DQ2/DQ8 Testing

HLA genotyping is the one component of celiac workup unaffected by any medication or diet. A patient who is HLA-DQ2 and DQ8 negative has a negative predictive value of 99% for celiac disease and does not need ongoing serologic surveillance regardless of symptom persistence [4].

Lab Ordering Considerations Across Common Clinical Scenarios

Getting the right result depends as much on ordering strategy as on laboratory technique.

Scenario A: New diagnosis workup, patient on no GFD

Order the full panel: tTG-IgA, EMA-IgA, DGP-IgG, and total IgA. If total IgA is deficient, the IgA-based markers are unreliable and DGP-IgG becomes the primary diagnostic test.

Scenario B: Patient already on GFD for more than 6 months

Do not order the panel without context. If pre-test probability is high (iron deficiency anemia, family history, autoimmune thyroid disease), proceed with HLA-DQ2/DQ8 genotyping first. If HLA positive, discuss a structured gluten challenge before serology. If HLA negative, celiac is effectively excluded [4].

Scenario C: Patient on immunosuppressants

Note the medication on the requisition. Interpret tTG-IgA as a lower-bound estimate of actual disease activity. Add DGP-IgG (both IgA and IgG variants). Consider referral for biopsy if clinical suspicion remains high despite negative serology, because mucosal damage may be present even when antibodies are suppressed [9].

Scenario D: Monitoring after confirmed diagnosis

Test tTG-IgA alone (add total IgA every 1 to 2 years to detect new-onset IgA deficiency). EMA-IgA adds cost without additional monitoring value once a diagnosis is established. DGP-IgG is useful if tTG-IgA is suppressed by immunotherapy.

Celiac Panel in the Context of Iron Deficiency and B12 Deficiency Workup

Iron-deficiency anemia without an identified bleeding source is an independent indication for celiac serologic testing in adults. A meta-analysis published in the American Journal of Gastroenterology found that the prevalence of biopsy-confirmed celiac disease in adults with unexplained iron-deficiency anemia was 3.8% (95% CI 2.4 to 5.5%), roughly 5-fold higher than population prevalence [17].

Vitamin B12 deficiency in celiac disease is less common than iron deficiency because B12 absorption occurs in the terminal ileum, which is typically less affected by celiac-related mucosal injury than the proximal intestine. Still, a 2016 cross-sectional study (N=310 adults with newly diagnosed celiac disease) found B12 deficiency in 11% of patients at diagnosis [18]. Checking a celiac panel in patients with unexplained B12 deficiency and no dietary or gastric cause is reasonable clinical practice.